Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the article by Singh and Cleveland
| Autor: | Fernando Pérez Ruiz, Neus Quilis, Eliseo Pascual, Boris Anthony Blanco Cáceres, Mariano Andrés, Francisca Sivera, Paloma Vela, Enrique Calvo-Aranda, Cesar Diaz-Torne, Alejandro Prada-Ojeda |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
musculoskeletal diseases
0301 basic medicine medicine.medical_specialty crystal arthropathies Gout Allopurinol Immunology MEDLINE Arthritis Hyperuricemia General Biochemistry Genetics and Molecular Biology Gout Suppressants 03 medical and health sciences gout 0302 clinical medicine Febuxostat Rheumatology medicine Crystal arthropathy Immunology and Allergy Humans Adverse effect 030203 arthritis & rheumatology business.industry musculoskeletal neural and ocular physiology Incidence (epidemiology) medicine.disease Dermatology 030104 developmental biology arthritis business medicine.drug |
| Zdroj: | ANNALS OF THE RHEUMATIC DISEASES r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau instname r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante r-FISABIO: Repositorio Institucional de Producción Científica Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO) |
| ISSN: | 1468-2060 0003-4967 |
| Popis: | Dear Editor, We read with interest the recent article by Singh and Cleveland on the hypersensitivity risk of allopurinol (ALP) and febuxostat (FBX) compared with colchicine.1 A common challenge when using ALP, linked to hypersensitivity reactions, is the potential development of cutaneous adverse reactions (CARs). Most are often mild, non-specific rashes; however, severe CARs, including Stevens-Johnson syndrome (SJS), may occur, but with a low incidence (0.69 cases per 1000 person-years) in non-Asian populations.2 In the EuroSCARs study, ALP was the reason for 5% of all severe CARs.3 So, FBX is often chosen as urate-lowering agent on the background of an ALP-related CAR. However, these patients were not eligible for the pivotal trials of FBX4 and were excluded from the recent analysis by Singh and Cleveland.1 Therefore, the accurate rate of FBX-related CARs in patients who previously suffered from ALP, and the mechanisms behind, remain undetermined to date. We have … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|